Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

<div>The meta-analysis results of afatinib efficacy and safety in advanced NSCLC with EGFR mutation: (a) the outcome of progression-free survival (PFS); (b) the outcome for overall survival (OS); and (c) the outcome for time to failure (TTF).</div>

Journal of Oncology

fig3

Figure 3

Figure 3: Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 

Figure 3 | Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 